Inborn errors of metabolism:

Indications for: ZAVESCA

Mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not feasible.

Adult Dosage:

≥18yrs: 100mg 3 times daily; may reduce to 100mg once or twice daily if diarrhea or tremor occurs. Mild renal impairment (CrCl 50–70mL/min): 100mg twice daily. Moderate renal impairment (CrCl 30–50mL/min): 100mg once daily. Severe renal impairment: not recommended.

Children Dosage:

<18yrs: not established.

ZAVESCA Warnings/Precautions:

Perform neurological evaluations at baseline, then periodically at 6-month intervals. Reevaluate and consider discontinuation if signs/symptoms of peripheral neuropathy develop (eg, numbness, tingling). GI disease (eg, inflammatory bowel). Monitor platelets. Renal impairment. Elderly. Pregnancy. Nursing mothers: not recommended.

ZAVESCA Classification:

Glucosylceramide synthase inhibitor.

ZAVESCA Interactions:

May antagonize imiglucerase.

Adverse Reactions:

Diarrhea, weight loss, tremor, flatulence, abdominal pain, GI disturbances, weakness, headache, dizziness, paresthesia, cramps, vision problems, thrombocytopenia, back pain, dry mouth, menstrual changes; reduced spermatogenesis, peripheral neuropathy.

Generic Drug Availability:


How Supplied:

Caps—18, 90